The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
The joint partnership, powered by Cloudbyz Clinical Research Management Platform and ClinChoice's industry-leading transformation services, will provide an end-to-end clinical research management technology platform and services to customers
Both companies have been selected for stand-by production by German government
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
Researchers from the Tel Aviv University successfully engineer the world's first 3D human spinal cord tissue transplant
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Subscribe To Our Newsletter & Stay Updated
